129 related articles for article (PubMed ID: 37310065)
41. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria.
Zen Y; Adsay NV; Bardadin K; Colombari R; Ferrell L; Haga H; Hong SM; Hytiroglou P; Klöppel G; Lauwers GY; van Leeuwen DJ; Notohara K; Oshima K; Quaglia A; Sasaki M; Sessa F; Suriawinata A; Tsui W; Atomi Y; Nakanuma Y
Mod Pathol; 2007 Jun; 20(6):701-9. PubMed ID: 17431410
[TBL] [Abstract][Full Text] [Related]
42. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
43. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.
Itatsu K; Zen Y; Ohira S; Ishikawa A; Sato Y; Harada K; Ikeda H; Sasaki M; Nimura Y; Nakanuma Y
Liver Int; 2007 Nov; 27(9):1174-84. PubMed ID: 17919228
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma.
Wu WR; Shi XD; Zhang R; Zhu MS; Xu LB; Yu XH; Zeng H; Wang J; Liu C
Int J Clin Exp Pathol; 2014; 7(6):3272-9. PubMed ID: 25031748
[TBL] [Abstract][Full Text] [Related]
47. Molecular mechanism of cholangiocarcinoma carcinogenesis.
Maemura K; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
[TBL] [Abstract][Full Text] [Related]
48. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
[TBL] [Abstract][Full Text] [Related]
49. Extensive biliary intraepithelial neoplasia (BilIN) and multifocal early intrahepatic cholangiocarcinoma in non-biliary cirrhosis.
Rougemont AL; Genevay M; McKee TA; Gremaud M; Mentha G; Rubbia-Brandt L
Virchows Arch; 2010 Jun; 456(6):711-7. PubMed ID: 20428886
[TBL] [Abstract][Full Text] [Related]
50. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis.
Charbel A; Tavernar L; Albrecht T; Brinkmann F; Verheij J; Roos E; Vogel MN; Köhler B; Springfeld C; Brobeil A; Schirmacher P; Singer S; Mehrabi A; Roessler S; Goeppert B
Br J Cancer; 2022 Nov; 127(9):1603-1614. PubMed ID: 36068277
[TBL] [Abstract][Full Text] [Related]
51. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
52. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
53. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
54. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.
Sasaki M; Nitta T; Sato Y; Nakanuma Y
Am J Clin Pathol; 2016 Jun; 145(6):815-25. PubMed ID: 27334809
[TBL] [Abstract][Full Text] [Related]
55. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement.
Zen Y; Aishima S; Ajioka Y; Haratake J; Kage M; Kondo F; Nimura Y; Sakamoto M; Sasaki M; Shimamatsu K; Wakasa K; Park YN; Chen MF; Atomi Y; Nakanuma Y
Pathol Int; 2005 Apr; 55(4):180-8. PubMed ID: 15826244
[TBL] [Abstract][Full Text] [Related]
56. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
[TBL] [Abstract][Full Text] [Related]
57. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
58. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
[TBL] [Abstract][Full Text] [Related]
59. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
60. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
